Extina 2% ketoconazole: CNCT started a 600-patient double-blind, placebo-controlled U.S. Phase III study of Extina to treat seborrheic dermatitis.

Connetics Corp. (CNCT), Palo Alto, Calif.

Read the full 62 word article

How to gain access

Continue reading with a
two-week free trial.